PDCD1 and neoplasm: CTLA-4 inhibitors (ipilimumab and tremelimumab) act during T-cell priming [23,24,25], while PD-1 inhibitors (cemiplimab, nivolumab, and pembrolizumab) counter tumor-mediated suppression [26,27].